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Photodynamic therapy (PDT) of solid tumours causes tissue damage that elicits local and systemic inflammation with major
involvement of interleukin-6 (IL-6). We have previously reported that PDT-treated cells lose responsiveness to IL-6 cytokines.
Therefore, it is unclear whether PDT surviving tumour cells are subject to regulation by IL-6 and whether this regulation could
contribute to tumour control by PDT. We demonstrate in epithelial tumour cells that while the action of IL-6 cytokines through their
membrane receptors is attenuated, regulation by IL-6 via trans-signalling is established. Soluble interleukin-6 receptor-a (IL-6Ra)( s I L - 6 R a)
and IL-6 were released by leucocytes in the presence of conditioned medium from PDT-treated tumour cells. Cells that had lost their
membrane receptor IL-6Ra due to PDT responded to treatment with the IL-6R–IL-6 complex (Hyper-IL-6) with activation of signal
transducers and activator of transcription (STAT3) and ERK. Photodynamic therapy-treated cells, which were maintained during post-
PDT recovery in presence of IL-6 or Hyper-IL-6, showed an enhanced suppression of proliferation. Cytokine-dependent inhibition of
proliferation correlated with a decrease in cyclin E, CDK2 and Cdc25A, and enhancement of p27kip1 and hypophosphorylated Rb.
The IL-6 trans-signalling-mediated attenuation of cell proliferation was also effective in vivo detectable by an improved Colon26
tumour cure by PDT combined with Hyper-IL-6 treatment. Prevention of IL-6 trans-signalling using soluble gp130 reduced curability.
The data suggest that the post-PDT tumour milieu contains the necessary components to establish effective IL-6 trans-signalling, thus
providing a means for more effective tumour control.
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Photodynamic therapy (PDT) is an effective therapy for local
malignant tumours, which uses the activation of tumour-localising
photosensitising agents by visible light (Henderson and Gollnick,
2003). It results in the local generation of cytotoxic singlet oxygen
and other reactive oxygen species, setting in motion a sequence of
photochemical and photobiological processes that can cause
irreversible oxidative damage to cells of the tumour parenchyma
and stroma (Girotti, 2001). The initiating event is the immediate
oxidative modification of lipids and proteins, followed by cell
signalling events that over minutes to hours result in changes in
gene expression (Luna et al, 1994; Kick et al, 1996), stress
responses, repair reactions and/or activation of cell death
mechanisms (Ahmad et al, 1998; Wong et al, 2003; Zhuang et al,
2003). In particular, photo-oxidation of plasma membrane lipids
leads to accelerated phospholipid degradation and generation of
potent inflammatory mediators (Korbelik, 1996; Girotti, 2001).
Increased expression of specific cyto- and chemokines, and
vascular adhesion molecules creates a tumour milieu that within
hours attracts host inflammatory immune cells, neutrophils and
macrophages (Gollnick et al, 1997, 2003). Inflammation has been
identified as an important contributor to long-term tumour
control by PDT (de Vree et al, 1996; Henderson et al, 2004)
through stimulation of an antitumour immune response (Gollnick
et al, 2006; Korbelik et al, 1996a,b).
Interleukin-6 (IL-6) mRNA and protein are upregulated in certain
tumour cells after PDT in vitro and IL-6 is generally the most
markedly enhanced cytokine in tumour tissues after PDT in vivo
(Kick et al, 1995; Gollnick et al, 1997). The biological activities of
IL-6 are classically mediated through binding to a membrane-bound
cognate receptor interleukin-6 receptor-a (IL-6Ra)( g p 8 0 )a n d
triggering of a signal transducer, gp130 (Kishimoto et al, 1995; Hibi
et al, 1996). Upon activation, gp130-derived signals alter many
cellular functions, such as cell proliferation and survival, differentia-
tion, mobility and angiogenesis (Hirano et al, 2000; Wei et al, 2003).
We have reported earlier that PDT can abolish cellular
responsiveness to cytokines and growth factors, including IL-6,
through the loss of their respective membrane receptors, which
would render the abundantly present IL-6 in the tumour
environment ineffective (Wong et al, 2003). However, many of
the biological activities assigned to IL-6 can also be mediated via a
soluble form of the cognate IL-6 receptor-a (sIL-6Ra) during acute
inflammation. The soluble IL-6R can be generated by two distinct
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smechanisms, namely, by proteolytic cleavage of the membrane
receptor or by translation of a differentially spliced mRNA (Rose-
John and Heinrich, 1994). The sIL-6Ra forms an agonistic complex
with IL-6 and binds membrane gp130 to trigger cellular responses
in a process termed IL-6 trans-signalling (Rose-John and Heinrich,
1994). We hypothesise that IL-6 trans-signalling can compensate in
part for PDT-induced loss of signalling through the membrane-
bound IL-6Ra, thus providing IL-6 responsiveness in the post-PDT
tumour environment. Our current study demonstrates for the first
time that significant amounts of sIL-6Ra, capable of mediating the
effects of PDT-induced IL-6, can be expected to be generated in the
tumour environment. They further show that this enhances
tumour control by PDT.
MATERIALS AND METHODS
Cell culture
Tumour cell lines were obtained from the American Type Culture
Collection (Rockville, MD, USA). Human cervical carcinoma cell
lines HeLa and C33A were maintained in DMEM supplemented
with 2mML -glutamine, 1% streptomycin–penicillin, gentamicin
(100mgml
 1) and 10% foetal bovine serum (FBS). Murine Colon26
(colon carcinoma) cells were maintained in RPMI-1640 medium
with 10% FBS and 1% streptomycin–penicillin. Human macro-
phages were obtained from the lung parenchyma of patients
undergoing thoracic surgery (Loewen et al. 2005).
Animals and tumour system
Colon26 tumours were propagated in pathogen-free BALB/cJ mice
(Jackson Laboratory, Bar Harbor, ME, USA). Animals were housed
in microisolator cages in a laminar flow unit under ambient light.
Six- to 12-week-old animals were inoculated intradermally on the
right and/or left shoulder with 10
6 tumour cells harvested from
exponentially growing cultures. Tumours were used for experi-
mentation B10 days after inoculation when they had reached
6–8mm in diameter. The RPCI Institutional Animal Care and Use
Committee approved all of the procedures carried out in this
study.
Photosensitiser
Clinical-grade, pyrogen-free 2-[1-hexyloxyethyl]-2-devinyl pyro-
pheophorbide-a (HPPH) was obtained from the Roswell Park
Pharmacy (Buffalo, NY, USA) and reconstituted to 0.4mM in
pyrogen-free 5% dextrose containing 2% ethanol and 0.1% Tween.
Photodynamic therapy treatment
For in vitro experiments, cells at subconfluence were incubated in
the dark at 371C for 4h with medium containing HPPH doses as
indicated in the text. Medium was replaced by HPPH-free medium
and the cells were exposed to 665nm laser light at a fluence of 1 or
2Jcm
 2 and a fluence rate of 7 or 14mWcm
 2 (see description of
individual experiments).
For in vivo experiments, animals were injected via tail vein with
0.4mmolkg
 1 HPPH. After 24h, hair was removed from the
treatment site and from the site that served as unilluminated
controls by shaving and depilation with Nair shaver (Carter-
Wallace, Inc., New York, NY, USA). Mice were immobilised in
specially designed Plexiglas holders without anaesthesia during the
course of light delivery. A spot, 1.1cm in diameter, was exposed to
a fluence of 88 or 128Jcm
 2 at a fluence rate of 14mWcm
 2.
The light source consisted of a dye laser (375; Spectra-Physics,
Mountain View, CA, USA) pumped by an argon-ion laser (2080;
Spectra-Physics), using DCM dye (Exciton, Dayton, OH, USA). The
dye laser was tuned to 665nm. Output from the dye laser was
passed through an eight-way beam splitter, and the power of each
beam was set individually with Brewster window-type attenuators.
Reagents
Rabbit antibodies against phosphorylated (Y705)-signal transdu-
cers and activator of transcription (STAT)3, phosphorylated p38,
PARP, Erk1/2, Bax, and Bcl-xL and mouse monoclonal antibodies
against phospho-Erk1/2 were purchased from Cell Signaling
Technology (Beverly, MA, USA); rabbit antibodies against STAT3,
Bcl-2, cyclin D1, cyclin E1, Cdk2, Cdc25A, p21
Cip1 and p27
Kip1
p21
Cip1 and p27
Kip1 were purchased from Santa Cruz Biotechnology
(Santa Cruz, CA, USA) and rabbit antibody against RB was pur-
chased from BD Pharmingen (San Diego, CA, USA). Recombinant
human sgp130 was purchased from R&D Systems (Minneapolis,
MN, USA). The expression vector and production of Hyper-IL-6
was described previously (Fischer et al, 1997; Chattopadhyay et al,
2007).
RNA isolation and reverse transcription-PCR
Total RNA was prepared by using Trizol (Invitrogen, Carlsbad, CA,
USA) according to the manufacturer’s instructions. In total, 3mgo f
total RNA was reverse-transcribed with 200U of SuperScript III
reverse transcriptase (Invitrogen) and 0.5nmol of oligo (dT)12–18
primer, then polymerase chain reaction (PCR) was performed in
25ml of reaction solution containing cDNA derived from 50ng of
total RNA, 1U of Taq DNA polymerase (Roche), 2.5nmol of each
dNTP (Roche) and 2pmol of sense and antisense primer pairs
shown below with a DNA thermal cycler. PCR cycles were operated
on a regimen of 30s of denaturation of 941C; 30s of primer
annealing at the temperature as below and 45s extension/synthesis
at 721C for 35 cycles. Integrity of the obtained cDNA was tested by
amplification of GAPDH transcripts in a 25-cycle PCR reaction.
The primers, annealing temperatures and lengths of PCR products
are as follows: human (h) IL-6-sense: 50-CCCCAGTACCCCCAGGA
GAAGA-30, h-IL-6-antisense: 50-GCTGCGCAGAATGAGATGAGTT
GT-30, annealing temperature 551C, size 509bp; h-IL-6R-sense:
50-CATTGCCATTGTTCTGAGGTTC-30,h - I L - 6 R - a n t i s e n s e :5 0-GTGCC
ACCCAGCCAGCTATC-30, annealing temperature 631C, size 280bp;
h-sIL-6R-sense: 50-GCGACAAGCCTCCCAGGTTC-30, h-sIL-6R-anti-
sense: 50-GTGCCACCCAGCCAGCTATC-30, annealing temperature
631C, size 278bp; h-oncostatin M receptor (OSMR)-sense 50-ACCCGG
AAGAAAAGGCATTGATT-30, h-OSMR-antisense: 50-ACTTGGGGCT
TTTGGGGATACTG-30, annealing temperature 551C, size 569bp;
gp130-sense: 50-CATAGTCGTGCCTGTTTGCTTAG-30,g p 1 3 0 - a n t i -
sense: 50-GATCTTCTGGCCGCTCCTC-30, annealing temperature
551C, size 527bp; GAPDH-sense: 50-TGAACGTCGGTGTGAACGGA
TTTGGC-30; GAPDH-antisense: 50-CATGTAGGCCATGAGGTCCACC
AC-30, annealing temperature 551C. In all, 20ml of PCR products
were depicted by electrophoresis on 2.0% agarose gels containing
ethidium bromide, visualised by UV light and photographed.
Immunofluorescence
Immunofluorescence staining of HeLa cells was performed with
standard techniques using polyclonal rabbit antibodies against the
C-terminus of IL-6Ra of human origin (Santa Cruz, C-20). Cells to
be analysed by staining were fixed for 15min at room temperature
in 2% paraformaldehyde, permeabilised in 0.25% Triton X-100 for
30s, washed twice in phosphate-buffered saline (PBS), and then
blocked by incubation in 2.5% bovine serum albumin (BSA) in
PBS. Polyclonal rabbit anti-human IL-6 receptor antibody was
applied to the slides at a dilution of 1:100 and incubated for
60min at room temperature and then washed three times with
PBS. After incubation with fluorescein isothiocyanate (FITC)-
conjugated goat anti-rabbit secondary antibody (Sigma, St Louis,
MO, USA) at a dilution of 1:200 for 60min at room temperature,
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ssamples were washed three times with PBS. DNA was stained by
4,6-diamidino-2-phenylindole (DAPI). The immunofluorescence-
labelled cells were then analysed by fluorescence microscopy.
Controls of background staining (controls without primary
antibody) were processed in parallel.
Fluorescence-activated cell sorter analysis
Expression of receptor molecules at the cell surface was measured
by fluorescence-activated cell sorter (FACS). Briefly, subconfluent
monolayer culture cells were released with nonenzymatic dissocia-
tion buffer solution (Sigma Chemicals, St Louis, MO, USA),
followed by washing two times with sterile PBS, suspension in
staining buffer (PBS containing 2% foetal calf serum and 0.09%
sodium azide) and staining for 30min on ice with phycoerythrin-
conjugated anti-IL-6Ra (CD126) antibody (BD Pharmingen).
Analysis was performed on a FACSCalibur System using the Cell
Quest software (BD Pharmingen).
For cell cycle analysis, cells were harvested, washed and lysed in
ice-cold modified Vindelov buffer (0.1% sodium citrate, pH 7.4,
0.02mgml
 1 RNAse A, 0.37% NP-40, 0.5mgml
 1 propidium
iodide (PI)) in the dark. The intensity of PI labelling in the isolated
nuclei was then measured on a FACScan flow cytometer (Becton
Dickinson, Franklin Lakes, NJ, USA).
Cytokine and soluble receptor measurement
Cell culture supernatant was analysed for cytokine production with
a multiplex bead array format using the Bio-Plex/Luminex
Instrument. In total, 50ml per sample was analysed on the
Luminex 100 (Bio-Rad, Hercules, CA, USA). For the detection of
sIL-6Ra in supernatants, cells were seeded at a concentration of 10
6
cellsml
 1. Supernatants were taken at the indicated interval after
treatment. An enzyme-linked immunosorbent assay (ELISA) kit was
used (R&D Systems) according to the manufacturer’s instructions.
Western blot analysis
Aliquots of cell extracts containing 20mg of protein were
electrophoresed on 6–12% polyacrylamide gels. The proteins were
transferred to nitrocellulose membranes (Schleicher & Schuell,
Keene, NH, USA) and reacted with the indicated antibodies.
Appropriate peroxidase-conjugated secondary antibodies (ICN
Biomedicals, Aurora, OH, USA) were used in PBS containing 0.1%
Tween 20 and 5% milk. Immune complexes were visualised by
enhanced chemiluminescence reaction (Pierce Biotechnology,
Rockford, IL, USA). In each experimental series, X-ray films were
exposed for different lengths of time to obtained images with
quantitative signals in the linear range of densitometry. Equal
loading of samples was verified by Ponceau staining of the proteins
immediately after transfer to the nitrocellulose membrane.
Clonogenic assay
Cells were seeded in 10cm Petri dishes and left to adhere overnight
in regular growth medium as described. 2-[1-Hexyloxyethyl]-2-
devinyl pyropheophorbide-a and/or IL-6 cytokines were added as
indicated in the text. After PDT treatment, cells were trypsinised
and plated in growth medium for colony formation. Two separate
experiments were performed using duplicate samples.
DNA synthesis
DNA synthesis was determined by [
3H]thymidine incorporation.
Briefly, cells were seeded into 24-well culture plates (5 10
4 cells
per well). After 48h, 1mCi of [
3H]thymidine (Amersham
Biosciences) was added to each culture and incubation continued
for an additional 16h. Cells were released by trypsin and collected
onto paper filter by the cell harvester (Tomtec, Hamden, CT, USA).
The amount of incorporated tritium was measured by a
scintillation counter (Trilux microbeta, Perkin-Elmer Wallac,
Turku, Finland).
Assessment of tumour response
Orthogonal diameters of tumours were measured once every 2
days with calipers. The tumour volume, V, was calculated with the
formula V¼(lw
2/2), where l is the longest axis of the tumour, and
w is the axis perpendicular to l. The tumours were monitored until
they reached a volume 4400mm
3, at which time the mice were
killed. Regrowing tumours reached the 400mm
3 volume within
B10 days. No tumour regrowth was ever observed later than
Bday 50 and therefore animals were considered cured if they
remained tumour free for at least 60 days after PDT.
Statistical evaluation
The one-tailed Student’s t test was used for comparison between
groups in all of the experiments except for tumour response
determinations, with P-values of 0.05, representing statistical
significance. For tumour response data analysis, hours to event
(i.e., to 400mm
3 tumour volume) were calculated for each animal
by linearly interpolating between the times just before and after
this volume was reached, using log (tumour volume) for the
calculations; both tumour volume and hours-to-event calculations
were performed using Excel (Microsoft, Redmond, WA, USA).
Time to progression, defined as a function of time to tumour
growth of greater than 400mm
3, was determined using a Cox
regression model.
RESULTS
Conditioned medium from PDT-treated HeLa cells induces
macrophages to release sIL-6Ra
To identify whether PDT might create a milieu that would favour
IL-6 trans-signalling, we employed a culture system of HeLa cells
and primary human lung macrophages, representing the interacting
components of tumour and inflammatory cells. These human cell
types were used for the basic assessment of PDT action on IL-6
receptor system because immune reagents were available that
permitted the quantification of soluble human IL-6Ra. First we
established that HeLa cells, like other cell types, release increased
amounts of IL-6 into the culture medium in response to PDT in a
dose-dependent manner (Figure 1A, black bars). The same
conditioned medium (CM) did not contain appreciable levels of
sIL-6Ra (Figure 1A, grey bars). Transfer of 24-h CM from control
(HPPH – but not light – treated) HeLa cell culture to macrophages
stimulated in these the secretion of IL-6 (Figure 1B). In contrast,
conditioned media from HeLa cells treated with increasing dose of
PDT were progressively less effective in stimulating IL-6 produc-
tion by macrophages (Figure 1B). The same conditioned media,
however, increased up to three-fold the release of sIL-6Ra
(Figure 1C). Given the fact that the in vivo tumour milieu contains
copious amounts of IL-6 after PDT and macrophages are a
component of the PDT-induced host cell infiltrate (Gollnick et al,
1997; Henderson et al, 2004), these findings argue for a possible
role of sIL-6Ra and IL-6/sIL-6Ra complex in PDT-treated tumours.
Interleukin-6 trans-signalling is maintained by
PDT-treated tumour cells that have lost their membrane
IL-6Ra
One of the striking biological consequences of PDT is that
surviving cells transiently lose responsiveness to cytokines, such as
to IL-6 (Wong et al, 2003). Immunofluorescent staining of HeLa
cells confirmed that HPPH-PDT caused immediate loss of the
IL-6 trans signalling and photodynamic therapy
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scognate membrane-bound IL-6Ra (Figure 2A). RNA analysis
revealed that mRNAs for cognate IL-6Ra as well as for sIL-6Ra
encoded by an alternatively spliced transcript were retained by
PDT-treated cells (Figure 2B), suggesting that post-PDT recovery
of the cells could resume IL-6R synthesis from pre-existing mRNA
pool. Although not quantitative, the PCR data nevertheless
suggested a trend toward reduced mRNA for both IL-6R forms
in cells exposed to higher PDT dose (Figure 2B, right panel). The
same cells also indicated a PDT-dose and time-dependent increase
of IL-6 mRNA in agreement with the known effects including
stress-induced expression of IL-6 (Kick et al, 1995, 1996; Gollnick
et al. 1997). The cells also showed that PDT did not cause an
appreciable change in mRNA for the co-expressed receptor
subunits, OSMRb and gp130 (Figure 2B, left panel).
We next addressed the question whether sIL-6Ra when added
together with IL-6 to PDT-treated cells would elicit a response
through trans-signalling by engaging gp130. To test this, HeLa cells
after exposure to PDT were treated with the designer cytokine
Hyper-IL-6 and the response compared to that of IL-6 treatment.
The response to cytokine was monitored by the level of STAT3 and
ERK phosphorylation (Figure 2C). Photodynamic therapy reduced
the STAT3 response to IL-6 by 90%, but that to Hyper-IL-6 only by
30%. The presence of crosslinked STAT3 complexes, which are
known to correspond to absorbed PDT dose (Liu et al, 2004;
Henderson et al, 2007), indicated that the individual cultures
within each experimental group had received comparable PDT
exposure. Taken together, this suggests a preferential PDT-
mediated inactivation of IL-6Ra over gp130, the latter still being
able to engage the IL-6/sIL-6Ra complex.
To demonstrate that Hyper-IL-6 was able to function in PDT-
treated cells independently of the membrane IL-6Ra, the IL-6R-
null C33A tumour cell line was subjected to the same PDT
treatment as HeLa cells. Signalling in response to Hyper-IL-6
following PDT proved to be similar to that detected in HeLa cells
(Figure 2D). Taken together, these data suggest that IL-6 trans-
signalling can occur in the post-PDT tumour environment and
that it may affect PDT-surviving tumour cells that have lost their
IL-6Ra or cells that are inherently IL-6Ra negative.
IL-6 trans-signalling affects cell proliferation following
PDT
The cellular responses to IL-6 stimulation in the presence of
functioning signal transduction mechanisms range from growth
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Figure 1 Induction of IL-6 and sIL-6Ra following PDT. (A) HeLa cells were treated with increasing concentrations of HPPH and irradiated with 1Jcm
 2
light. Conditioned media were collected at 24h post PDT. (B, C) Pulmonary macrophages were incubated for 24h with CM from PDT-treated HeLa cells.
The concentrations of IL-6 and sIL-6Ra in the supernatant culture media were determined by Bio-Plex/Luminex and ELISA, respectively. The values in each
experimental series were normalised to the untreated controls and the relative changes determined in three independent experiments were expressed as
mean and SD. Values indicated by stars denote difference with Po0.05 compared to controls. As reference, the average concentrations for control cultures
were as follows: (A) IL-6: 180pgml
 1, sIL-6Ra:1 0p gm l
 1;( B) IL-6 for CM-0 culture: 32ngml
 1;( C) sIL6Ra: 100pgml
 1.
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spromotion to growth inhibition (Taga et al, 1989; Novick et al,
1992). To address the question of potential effects of IL-6 trans-
signalling on the proliferation of PDT-surviving tumour cells, we
incubated HeLa cells with IL-6, or Hyper-IL-6, following graded
PDT doses and assessed survival and proliferation. Clonogenic
assay revealed that both IL-6 and Hyper-IL-6 of untreated control
cells tended to reduce proliferation, indicating that HeLa cells are
subject to some growth control by gp130-derived signals
(Figure 3A). Photodynamic therapy reduced in a dose-dependent
manner proliferation in the treated cell culture. Choosing PDT
conditions that led to a maximal 60% reduction of viable cells, the
treatment of the PDT-surviving cell populations with either IL-6 or
Hyper-IL-6 showed a further decline of proliferation. Hyper-IL-6
was more effective than IL-6 in suppressing proliferation
(Figure 3A) in agreement with the enhanced signalling capability
of this factor (Figure 2C). The trends seen in the clonogenic assays
were also observed when [
3H]thymidine incorporation was used as
an end point (Figure 3B).
Photodynamic therapy-dependent growth suppression
through IL-6 trans-signalling also occurs in mouse colon26
tumour cells
To apply the findings made in HeLa cells regarding PDT-
dependent changes in IL-6 regulation of cell proliferation to an
in vivo tumour model, we chose the murine colon cell line
Colon26. Colon26 cells, like HeLa cells, express endogenous IL-6R
system and have a prominent trans-signalling capability in
response to Hyper-IL-6 (Figure 4A). Colon26 cells showed an
HPPH-PDT dose-dependent photoreaction leading to STAT3
crosslinking (Figure 4A, upper panel), reduction of IL-6 and
Hyper-IL-6 responsiveness as evident from the loss of STAT3
phosphorylation (Figure 4A, middle panel) and cell killing
(Figure 4B). Colon26 cells also displayed a prominent post-PDT
activation of ERK activation (Figure 4A, lower panel) that largely
reflected the effect of oxidative stress response. Of note is that the
magnitude of this stress-dependent activation of the mitogen-
activated protein kinase (MAPK) pathway in Colon26 cells is
exceptionally high. The phenomenon of PDT-dependent increase
of the growth inhibitory activity of IL-6 and Hyper-IL-6 detected in
HeLa cells was also reproduced in Colon26 cells. The magnified
effect on proliferation was more prominently evident because
Colon26 cells are inherently nonreceptive to IL-6-mediated growth
control (Figure 4C). The effect of Hyper-IL-6 on PDT-treated cells
was also manifested in a cytokine dose-dependent reduction of
DNA synthesis as determined by thymidine incorporation
(Figure 4D) that was strikingly similar to that found in HeLa cells
(Figure 3B).
The assays employing cell count, thymidine incorporation or
clonogenic growth highlighted the reduction of proliferating cells
C
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Figure 2 IL-6 trans-signalling in post-PDT cells. (A) Interleukin-6Ra expression in HeLa cells was evaluated by immunofluorescence. Upper panel, cells
were seeded onto coverslips. Immediately after treatment with PDT (HPPH 0.4mM,1Jc m
 2), immunostaining was carried out using anti-IL-6Ra antibody
followed by FITC-conjugated secondary antibody. The nucleus was stained with 4,6-diamidino-2-phenylindole, and the labelled cells were observed by
fluorescence microscopy. Lower panel, expression of cell surface receptor molecules was measured by FACS analysis. Cells were stained for 30min on ice
with phycoerythrin-conjugated anti-IL-6Ra (CD126) antibody. (B) The effects of PDT on the mRNA levels of IL-6 and IL-6 receptors. HeLa cells were
treated with 0.4mM HPPH and 1Jcm
 2 of light, and mRNA was extracted at different time period post-PDT (left), or cells were treated with increasing
concentrations of HPPH and irradiated with 1Jcm
 2 of light, and mRNA was extracted at 24h post-PDT. Reverse transcription–PCR was performed using
primers specific for IL-6, IL-6Ra, sIL-6Ra, OSMR and gp130. The PCR products were separated on 2% agarose gel and visualised by ethidium bromide
staining. Glyceraldehyde 3-phosphate dehydrogenase served as an internal control. (C, D) Cytokine responsiveness in post-PDT cells. HeLa cells (C)o r
C33A cells (D) were treated with increasing concentrations of HPPH, irradiated with 1Jcm
 2 light. Cytokines (IL-6 100ngml
 1; Hyper-IL-6 160ngml
 1)
were added after PDT for 15min and cells were then extracted. Replicate aliquots of the extracts containing equal amounts of protein were analysed by
immunoblotting for the indicated protein.
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sin the PDT- and cytokine-treated cultures. However, the treated
cultures also contained viable but nonproliferating cells. Thus, the
cell cycle stage distribution of PDT-treated and surviving Colon26
cells cultures was evaluated by flow cytometry. When compared to
control cells, HPPH (0.8mM)-PDT-treated cells showed after 2 days
in culture an enhanced fraction of cells in the G1/G0 phase (66 vs
44%) with a concomitant reduction of cells in S and G2 phases. In
the presence of Hyper-IL-6 alone, Colon26 cells responded by
progressing through S to an accumulation in G2–M phase
resulting in a reduction of cells in G1/G0 phase to 42% and an
increase of cells in G2 from 22 to 31% (Figure 4E). The specific
effects of PDT on cell cycle distribution were maintained even
when Colon26 cells were treated with Hyper-IL-6, suggesting a
dominant effect of PDT on cell cycle control that is not subject to
change by Hyper-IL6. This regulatory phenotype may account, at
least in part, for the enhanced suppression of cell proliferation that
is observed by the combination of PDT and Hyper-IL-6 treatment.
Previous studies have suggested that IL-6 stimulation of
antiapoptotic or survival effects might assist cells to better
withstand PDT-mediated cytotoxicity (Jee et al, 2001). Consistent
with the above described decreased survival of PDT-treated cells in
the presence of IL-6 or Hyper-IL-6, culturing PDT-treated Colon26
cells with Hyper-IL-6 for 4h was unable to alter the PDT-induced
degradation of Bcl-2 and Bcl-xL and execution of caspase-
mediated apoptosis (Figure 5A). To extend the assessment to
other markers that correlate with growth regulation and, thus,
could provide information on the growth suppression by PDT and
Hyper-IL-6, we determined expression of representative cell cycle
proteins which had been shown to be associated with PDT (Ahmad
et al, 1998). Western blot analysis (Figure 5B) demonstrated a
substantial reduction of cyclin D1, cyclin E, Cdk2, Rb and p27Kip1
during the first 5–24h post-PDT period as compared to the
control. A recovery of expression was detected by 24–48h.
Addition of Hyper-IL-6 to PDT-treated cells did not detectably
alter the PDT-regulated expression of the cyclins and Rb, but
magnified the loss of Cdk2 and also elicited a reduction of
Cdc25A, which was not appreciable affected by PDT alone. In
contrast, Hyper-IL-6 was noted to increase p27 that, in the context
of post-PDT reaction, amounted to an attenuated suppression by
PDT. The more prominent changes in cell cycle controlling
proteins found for Hyper-IL-6-treated Colon26 cells would
account for the enhanced suppression of proliferation and
clonogenicity.
IL-6 trans-signalling enhances antitumour effects of PDT
in mice
Based on the in vitro results, we hypothesised that the combination
of IL-6 and sIL-6Ra is present in the tumour milieu and facilitates
IL-6 trans-signalling, which in turn has consequences for tumour
survival and proliferation. To test this hypothesis, we determined
whether IL-6 trans-signalling influences the in vivo tumour
response to PDT. To this end, we administered sgp130, which
selectively inhibits IL-6 trans-signalling, or Hyper-IL-6, which
magnifies trans-signalling, to mice carrying Colon26 tumours.
sgp130 was given 30min prior to the start of laser treatment and
3h after ending PDT treatment, at a time point when we expected
an increase of local IL-6 and sIL-6Ra and its neutralisation to be
optimal. The treatment of Hyper-IL-6 was started by an injection
before PDT and a follow-up injection 48h after PDT.
While tumour regrowth after PDT, when it occurred, com-
menced at the same time in sgp130 and control groups, and
proceeded at the same rate, sgp130 reduced the tumour cures
observed with PDT alone (Figure 6). In contrast, boosting IL-6
trans-signalling by administration of Hyper-IL-6 resulted in
increased tumour control. Similar to the experiments with
sgp130, tumour regrowth after PDT, when it occurred, commenced
at the same time in Hyper-IL-6 and control groups, and proceeded
at the same rate. However, tumour cures were enhanced by Hyper-
IL-6 administration from 0 to 20% with 88Jcm
 2 PDT (median
time to growth to 400mm
3 11.5 days and 13.3 days, respectively)
and from 20 to 60% with 128Jcm
 2 PDT (median time to growth
to 400mm
3 21.7 days and 460 days, respectively) (Figure 6).
While the effects of sgp130 administration can only be considered
a trend due to the limited number of animals tested, the effects of
Hyper-IL-6 administration were statistically significant (P¼0.03).
Cox regression model analysis revealed an estimated risk ratio of
regrowth to 400mm
3 and corresponding 95% confidence interval
for Hyper-IL-6¼absent to Hyper-IL-6¼present of 2.3 (1.1, 3.5).
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Figure 3 Interleukin-6 and Hyper-IL-6 suppress proliferation of PDT-treated HeLa cells. (A) HeLa cells were treated with increasing concentrations of
HPPH and exposed to 1Jcm
 2 of light. After irradiation, cells were plated in 6cm dishes in the presence or absence of IL-6 cytokines (IL-6 100ngml
 1;
Hyper-IL-6 160ngml
 1). After 14 days, colonies were fixed, stained with crystal violet and counted (colonies with 425 cells). The values represent means
of a single experiment performed in triplicate, representative of three performed. (B)[
3H]thymidine incorporation into HeLa cells. Post –PDT, cells were
treated or not treated with 160ngml
 1 Hyper-IL-6. [
3H]Thymidine incorporation after 48h of treatment is plotted as the mean±s.d. of a single experiment
performed in triplicate, representative of three independent experiments. *Po0.05, compared with the corresponding value of PDT alone.
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Figure 4 Effect of HPPH-PDT on Colon26 cells. (A) PDT dose-dependent crosslinking of STAT3 and loss of STAT3 signalling in Colon26 cells. Colon26
cells were incubated for 4h with the indicated concentration of HPPH and then exposed to 2Jcm
 2 light. Immediately following PDT, the cells were treated
with IL-6 or Hyper-IL-6 (100ngml
 1 each) for 15min. Cell extracts were analysed by immunoblotting for the degree of STAT3 crosslinking and treatment-
induced changes in phosphorylation of STAT3 and ERK1/2. (B) Colon26 cells were treated with HPPH-PDT treated in (A) and then incubated in full growth
medium for 24h. The numbers of surviving cells were determined by counting. Mean valuesþs.d. of four separate experimental series are presented. (C)
Recovery of proliferation of PDT-treated Colon26 cells. Cells collected after 24h incubation in (B) were diluted in culture medium, plated in replicate
cultures wells at o100 viable cellscm
 2, and cultured for 6 days in full growth medium alone, or medium containing in addition either 100ngml
 1 IL-6 or
Hyper-IL-6. The cell counts were determined and expressed relative to the cell counts in the medium control of each series. Meanþs.d. of four separate
cultures series in each PDT treatment group are shown. *Denotes Po0.05 compared to control. (D) Effect of PDT on [
3H]thymidine incorporation.
Colon26 cells were exposed to 1Jcm
 2, 0.4mM HPPH-PDT or not, and then treated with various concentrations of Hyper-IL-6. [
3H]thymidine
incorporation was assessed after 48h of treatment. Shown are the means±s.d. of a single experiment performed in triplicate, representative of three
performed. *Po0.001, compared with PDT alone;
#Po0.001, compared with corresponding non-PDT group. (E) PDT effect on cell cycle progression.
Colon26 cells were treated as indicated (PDT 0.4mM HPPH, 1Jcm
 2; Hyper-IL-6 160ngml
 1) and analysed 72h post-treatment. Cells were harvested,
stained with propidium iodide (PI) and subjected to FACScan flow cytometry. One representative of three independent experiments is shown as histogram.
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sDISCUSSION
Interleukin-6 membrane receptor (IL-6Ra) is mainly expressed by
hepatocytes, neutrophils, macrophages, lymphocytes and some
tumour cells (Scheller et al, 2006). Cells, which are deficient or lack
IL-6Ra, can respond to IL-6 when it is associated with a soluble
form of the IL-6Ra (sIL-6Ra) in a process called trans-signalling
(Rose-John and Heinrich, 1994). In this paper, we ask the question
whether the PDT-induced loss of IL-6 signalling function could be
overcome by trans-signalling mechanisms.
We show the generation of IL-6 by PDT-treated tumour cells as
well as by macrophages exposed to medium conditioned by these
tumour cells (Figure 1A and B). Interestingly, conditioned media
from PDT-treated HeLa cells were progressively less effective in
stimulating IL-6 production by macrophages, suggesting a PDT-
dependent loss or inactivation of the stimulatory activity factor. At
present, the identity of the cytokine-inducing factor with irritant-
like activity in conditioned HeLa culture medium has not yet been
established. Equally important, we demonstrate that exposure to
HeLa cell-CM leads to the generation of sIL-6Ra by macrophages
(Figure 1C), thus furnishing the components necessary for IL-6
trans-signalling. Chalaris et al (2007) have recently reported
shedding of IL-6R from neutrophils during apoptosis induced by
diverse mechanisms such as DNA damage, cytokine withdrawal,
Fas stimulation and UV exposure, and implicated caspase-
dependent activation of the metalloproteinase ADAM17 as the
critical event. Whereas in those experiments neutrophils were
exposed directly to the perturbing agent, in our case, the effects
were mediated indirectly through transfer of CM. Direct action of
PDT on HeLa cells did not generate sIL-6Ra (Figure 1A),
suggesting that PDT did not directly induce receptor shedding
although it abolished the membrane-bound IL-6Ra (Figure 2A)
(Wong et al, 2003). It is conceivable that the activation of the
ADAM17 metalloproteinase is involved in the IL-6Ra release by
HeLa-derived irritants in macrophages; however, the precise
molecular mechanism responsible for sIL-6Ra generation from
macrophages remains to be determined.
A major difference in the process by which macrophages and
neutrophils release sIL-6Ra is that the process in macrophages
apparently is not tied to apoptosis. Evidence for PDT-dependent
generation of regulatory factors or irritants has been detected by
Gollnick et al (2002) who determined that lysates from PDT-
treated tumour cells are able to mature dendritic cells and to
stimulate the release of cytokines.
Cells of gp130
þ/IL-6Ra
 /low phenotype, such as endothelial and
epithelial cells, in the post-PDT tumour environment can be
affected by the presence of IL-6 via trans-signalling mechanisms
(Figures 2 and 3). The cells’ response to IL-6 is mediated through
the JAK/STAT signal transduction pathway, where STAT3, after
phosphorylation, plays a central role in transmitting signals from
the membrane to the nucleus (Hirano et al, 2000). Rakemann et al
(1999) have shown that Hyper-IL-6 is a potent activator of STAT3-
dependent gene transcription. In cells of the B-cell lineage and in
plasmacytoma/myeloma cells, this facilitates transmission of
prosurvival signals, the enhancement of proliferation, differentia-
tion and inhibition of apoptosis by induction of the antiapoptotic
protein Bcl-xL; in hepatocytes, it leads to maturation and
enhancement of liver regeneration (Schwarze and Hawley, 1995;
Minami et al, 1996; Hirano et al, 2000). Overexpression of IL-6 has
been shown to either enhance or decrease sensitivity of tumour
cells to PDT-induced cytotoxicity by modulating apoptotic
threshold (Jee et al, 2001; Usuda et al, 2001). Conversely, IL-6
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Figure 5 The effects of Hyper-IL-6 on PDT-mediated effects on markers for apoptosis and cell cycle regulation in Colon26 cells. (A) Cells were treated
with increasing concentrations of HPPH and exposed to 1Jcm
 2 light. Following illumination, the cells were treated for 4h with various doses of Hyper-IL-6.
Cell lysates were separated on SDS–PAGE and the proteins indicated at the left were identified by immunoblotting. Results are representative of three
independent experiments. (B) Colon26 cells were subjected to 0.4mM HPPH and irradiated with 1Jcm
 2 of light. Immediately after illumination, the cells
were treated with or without 160ngml
 1 Hyper-IL-6. Cell lysates collected after the times indicated were analysed by immunoblotting for the proteins
marked at the left. a-tubulin served as an internal loading control (blots are not shown). Results are representative of three independent experiments.
Numbers below lanes represent relative staining intensities or the band relative to the untreated cultures in each series (defined as 100).
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scytokine family members oncostatin M and leukaemia inhibitory
factor (LIF) have been shown to suppress epithelial growth (Grant
et al, 2001).
In the present study it is evident that in PDT-treated cells, IL-6
exerts antiproliferative activity, similar to the suppression of
proliferation in epithelial cells by OSM (Chattopadhyay et al,
2007). In HeLa cells, IL-6 and even more so Hyper-IL-6 alone
reduced cell proliferation, and enhanced the antiproliferative
effects of PDT (Figure 3). In murine Colon26 cells, the growth of
which does not appear to be influenced by gp130 stimulation via
Hyper-IL-6 alone, the latter also induced prolonged growth arrest
after PDT (Figure 4). Studies by others have shown that PDT
disturbs cell cycle progression at the G1/S transition, which leads
to growth arrest and apoptosis (Ahmad et al, 1998; Haywood-Small
et al, 2006). The presence of Hyper-IL-6 enhanced and prolonged
the suppression of especially Cdk2. Our results further showed that
this decrease in Cdk2 is correlated with hypophosphorylation of
Rb (Figure 5B), which has been recognised to inhibit proliferation
through regulation of E2F-responsive genes (Ahmad et al, 1999). It
was shown earlier that PDT induced p21
WAF1/Cip1, which resulted
in a pronounced decrease in cyclin D1, Cdk2 expression and to a
lesser extent, cyclin E and Cdk6 (Ahmad et al, 1998). Our studies
disclose an increased p27
Kip1 and a decreased Cdc25A expression
by Hyper-IL-6 treatment in post-PDT cells (Figure 4), suggesting
that cdk2/cyclin E might be the molecular target involved in IL-6
trans-signalling-mediated cell cycle arrest. Supportive evidences
from previous studies showed that IL-6-type cytokines were able to
inhibit Cdk2 activity and DNA synthesis by accumulation of
p27
Kip1 protein (Klausen et al, 2000). Furthermore, it has been
reported that IL-6 was able to induce degradation of Cdc25A by
STAT3 activation, which would form a repressor complex with the
Rb tumour suppressor to occupy the Cdc25A promoter and block
its induction (Bernardi et al, 2000; Barre et al, 2005).
Considering the results of this study, one can construct the
following scenario. The post-PDT tumour milieu contains
abundant amounts of IL-6 and other inflammatory mediators
(Gollnick et al, 2003) to which surviving cells within the treatment
field do not respond directly because of PDT-induced degradation
and inactivation of their membrane-bound IL-6Ra. Leucocytes
respond to the tissue injury, enter the tumour environment,
generate sIL-6Ra as well as IL-6 and thus allow the transmission of
IL-6 signals in surviving tumour cells. Moreover, this also allows
stromal cells, which have a gp130
þ/IL-6Ra
 /low phenotype, to
respond to IL-6. While we may be able to credit the antiprolifera-
tive effects of IL-6 signalling for enhancing tumour control,
broader effects on the inflammatory response may well also be
involved. We and others have shown earlier that the inflammatory
response contributes to tumour control by PDT (Korbelik, 1996;
Henderson et al, 2004), and we have evidence that it contributes to
antitumour immunity (unpublished). Interleukin-6 is increasingly
recognised as critical for the successful resolution of inflammation
and as a major immunological switch from innate to acquired
immunity (Jones, 2005). Interleukin-6 signalling may also con-
tribute to antitumour immunity by inducing TH-17 cells in
collaboration with TGFb, while suppressing TGFb-driven Fox3
expression, which induces immunosuppressive regulatory T cells
(Bettelli et al, 2007). TH-17 cells produce IL-17, which coordinates
tissue inflammation by inducing inflammatory cytokines, chemo-
kines and matrix metalloproteinases capable of mediating tissue
infiltration and destruction.
In summary, this study has for the first time identified IL-6
trans-signalling as a mechanism orchestrating the tissue and host
response to PDT. As in preclinical models, clinical application of
PDT results in local and systemic inflammation, which can be
characterised by elevated cytokine levels, including IL-6. In severe
cases, this inflammatory response can constitute dose-limiting
toxicity and require pharmacological intervention (Yom et al,
2003). It is therefore of the utmost importance to fully understand
the mechanisms governing all aspects of the host response to PDT
and the consequences of this response for tumour control. Here we
provide evidence for the biological and possibly clinical relevance
of the IL-6 signalling pathways for the antitumour activity of PDT.
ACKNOWLEDGEMENTS
We thank Dr Sandra O Gollnick for valuable suggestions and
discussion, Ms Lurine Vaughan and Ms Barbara Owczarczak for
assistance in animal work, Tissue Procurement at RPCI for supply
of residual human lung tissue and Shiuan Wang for excellent
technical assistance.
REFERENCES
Ahmad N, Feyes DK, Agarwal R, Mukhtar H (1998) Photodynamic therapy
results in induction of WAF1/CIP1/P21 leading to cell cycle arrest and
apoptosis. Proc Natl Acad Sci USA 95: 6977–6982
Ahmad N, Gupta S, Mukhtar H (1999) Involvement of retinoblastoma (Rb)
and E2F transcription factors during photodynamic therapy of human
epidermoid carcinoma cells A431. Oncogene 18: 1891–1896
Barre B, Vigneron A, Coqueret O (2005) The STAT3 transcription factor is a
target for the Myc and riboblastoma proteins on the Cdc25A promoter.
J Biol Chem 280: 15673–15681
Bernardi R, Liebermann DA, Hoffman B (2000) Cdc25A stability is
controlled by the ubiquitin–proteasome pathway during cell cycle
progression and terminal differentiation. Oncogene 19: 2447–2454
100
Controls
88 J cm–2
88 J cm–2 Hyper-IL6 
88 J cm–2 sgp130 
128 J cm–2
128 J cm–2 Hyper-IL6
128 J cm–2 sgp130 80
60
40
20
0
0
10 20 30 40
Days post treatment
%
 
o
f
 
m
i
c
e
 
w
i
t
h
 
t
u
m
o
u
r
s
 
<
4
0
0
 
m
m
3
50 60
Figure 6 Effect of IL-6/sIL-6Ra on the outcome of PDT treatment of
Colon26 tumour growth. Mice carrying Colon26 tumours were treated
with 0.4mmolkg
 1 HPPH and irradiated with 88 or 128Jcm
 2 at
14mWcm
 2. Hyper-IL-6 (0.4mgmouse
 1) was given, intra peritoneum,
immediately and 48h after PDT. sgp130 (5mgmouse
 1) was given i.p.
30min before and 3h after PDT. Tumour growth was monitored for 60
days or until tumour reached a volume of 400mm
3. For clarity, data for
controls have been combined (total of 36 animals); controls included
untreated mice, mice with HPPH only and mice with HPPHþHyper-IL-6
but no light. All experimental groups consisted of 10–15 mice. Results are
reported as the percentage of animals with tumours o400mm
3. Animals
whose tumours had not reached 400mm
3 by 60 days were considered
cured.
IL-6 trans signalling and photodynamic therapy
L-H Wei et al
1521
British Journal of Cancer (2007) 97(11), 1513–1522 & 2007 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
sBettelli E, Oukka M, Kuchroo VK (2007) T(H)-17 cells in the circle of
immunity and autoimmunity. Nat Immunol 8: 345–350
Chalaris A, Rabe B, Paliga K, Lange H, Laskay T, Fielding CA, Jones S,
Rose-John S, Scheller J (2007) Apoptosis is a natural stimulus of IL6R
shedding and contributes to the pro-inflammatory trans-signaling
function of neutrophils. Blood 110: 1748–1755
Chattopadhyay S, Tracy E, Liang P, Robledo O, Rose-John S, Baumann H
(2007) Interleukin-31 and oncostatin-M mediate distinct signaling
reactions and response patterns in lung epithelial cells. J Biol Chem
282: 3014–3026
de Vree WJ, Essers MC, de Bruijn HS, Star WM, Koster JF, Sluiter W (1996)
Evidence for an important role of neutrophils in the efficacy of
photodynamic therapy in vivo. Cancer Res 56: 2908–2911
Fischer M, Goldschmitt J, Peschel C, Brakenhoff JP, Kallen KJ, Wollmer A,
Grotzinger J, Rose-John S (1997) A bioactive designer cytokine for
human hematopoietic progenitor cell expansion. Nat Biotechnol 15:
142–145
Girotti AW (2001) Photosensitized oxidation of membrane lipids: reaction
pathways, cytotoxic effects, and cytoprotective mechanisms. J Photochem
Photobiol B 63: 103–113
Gollnick SO, Evans SS, Baumann H, Owczarczak B, Maier P, Vaughan L,
Wang WC, Unger E, Henderson BW (2003) Role of cytokines in
photodynamic therapy-induced local and systemic inflammation. Br J
Cancer 88: 1772–1779
Gollnick SO, Liu X, Owczarczak B, Musser DA, Henderson BW (1997)
Altered expression of interleukin 6 and interleukin 10 as a result of
photodynamic therapy in vivo. Cancer Res 57: 3904–3909
Gollnick SO, Owczarczak B, Maier P (2006) Photodynamic therapy and
anti-tumor immunity. Lasers Surg Med 38: 509–515
Gollnick SO, Vaughan L, Henderson BW (2002) Generation of effective
antitumor vaccines using photodynamic therapy. Cancer Res 62: 1604–
1608
Grant SL, Douglas AM, Goss GA, Begley CG (2001) Oncostatin M and
leukemia inhibitory factor regulate the growth of normal human breast
epithelial cells. Growth Factors 19: 153–162
Haywood-Small SL, Vernon DI, Griffiths J, Schofield J, Brown SB (2006)
Phthalocyanine-mediated photodynamic therapy induces cell death and
a G0/G1 cell cycle arrest in cervical cancer cells. Biochem Biophys Res
Commun 339: 569–576
Henderson BW, Daroqui C, Tracy E, Vaughan L, Loewen GM, Cooper M,
Baumann H (2007) Cross-linking of signal transducer and activator of
transcription 3 (STAT3) – a molecular marker for the photodynamic
reaction in cells and tumors. Clin Cancer Res 13: 3156–3163
Henderson BW, Gollnick SO (2003) Mechanistic principles of photody-
namic therapy In Horspool W, Lenci F (eds) CRC Handbook of
Organic Photochemistry and Photobiology, 2 edn. pp 145-1–145-25.
Boca Raton, FL, USA: CRC Press
Henderson BW, Gollnick SO, Snyder JW, Busch TM, Kousis PC, Cheney
RT, Morgan J (2004) Choice of oxygen-conserving treatment regimen
determines the inflammatory response and outcome of photodynamic
therapy of tumors. Cancer Res 64: 2120–2126
Hibi M, Nakajima K, Hirano T (1996) IL-6 cytokine family and signal
transduction: a model of the cytokine system. J Mol Med 74: 1–12
Hirano T, Ishihara K, Hibi M (2000) Roles of STAT3 in mediating the cell
growth, differentiation and survival signals relayed through the IL-6
family of cytokine receptors. Oncogene 19: 2548–2556
Jee SH, Shen SC, Chiu HC, Tsai WL, Kuo ML (2001) Overexpression of
interleukin-6 in human basal cell carcinoma cell lines increases anti-
apoptotic activity and tumorigenic potency. Oncogene 20: 198–208
Jones SA (2005) Directing transition from innate to acquired immunity:
defining a role for IL-6. J Immunol 175: 3463–3468
Kick G, Messer G, Goetz A, Plewig G, Kind P (1995) Photodynamic therapy
induces expression of interleukin 6 by activation of AP-1 but not
NF-kappa B DNA binding. Cancer Res 55: 2373–2379
Kick G, Messer G, Plewig G, Kind P, Goetz AE (1996) Strong and prolonged
induction of c-jun and c-fos proto-oncogenes by photodynamic therapy.
Br J Cancer 74: 30–36
Kishimoto T, Akira S, Narazaki M, Taga T (1995) Interleukin-6 family of
cytokines and gp130. Blood 86: 1243–1254
Klausen P, Pedersen L, Jurlander J, Baumann H (2000) Oncostatin M and
interleukin 6 inhibit cell cycle progression by prevention of p27kip1
degradation in HepG2 cells. Oncogene 19: 3675–3683
Korbelik M (1996) Induction of tumor immunity by photodynamic therapy.
J Clin Laser Med Surg 14: 329–334
Korbelik M, Krosl G, Krosl J, Dougherty GJ (1996a) Modulation of tumor
response to photodynamic therapy in severe combined immunodeficient
(SCID) mice by adoptively transferred lymphoid cells. SPIE 2675: 156–162
Korbelik M, Krosl G, Krosl J, Dougherty GJ (1996b) The role of host
lymphoid populations in the response of mouse EMT6 tumor to
photodynamic therapy. Cancer Res 56: 5647–5652
Liu W, Oseroff AR, Baumann H (2004) Photodynamic therapy causes cross-
linking of signal transducer and activator of transcription proteins and
attenuation of interleukin-6 cytokine responsiveness in epithelial cells.
Cancer Res 64: 6579–6587
Loewen GM, Tracy E, Blanchard F, Tan D, Yu J, Raza S, Matsui S, Baumann
H (2005) Transformation of human bronchial epithelial cells alters
responsiveness to inflammatory cytokines. BMC Cancer 5: 145
Luna MC, Wong S, Gomer CJ (1994) Photodynamic therapy mediated
induction of early response genes. Cancer Res 54: 1374–1380
Minami M, Inoue M, Wei S, Takeda K, Matsumoto M, Kishimoto T, Akira S
(1996) STAT3 activation is a critical step in gp130-mediated terminal
differentiation and growth arrest of a myeloid cell line. Proc Natl Acad
Sci USA 93: 3963–3966
Novick D, Shulman LM, Chen L, Revel M (1992) Enhancement of
interleukin 6 cytostatic effect on human breast carcinoma cells by
soluble IL-6 receptor from urine and reversion by monoclonal antibody.
Cytokine 4: 6–11
Rakemann T, Niehof M, Kubicka S, Fischer M, Manns MP, Rose-John S,
Trautwein C (1999) The designer cytokine hyper-interleukin-6 is a potent
activator of STAT3-dependent gene transcription in vivo and in vitro.
J Biol Chem 274: 1257–1266
Rose-John S, Heinrich PC (1994) Soluble receptors for cytokines and
growth factors: generation and biological function. Biochem J 300: 281–290
Scheller J, Ohnesorge N, Rose-John S (2006) Interleukin-6 trans-signalling
in chronic inflammation and cancer. Scand J Immunol 63: 321–329
Schwarze MM, Hawley RG (1995) Prevention of myeloma cell apoptosis by
ectopic bcl-2 expression or interleukin 6-mediated up-regulation of
bcl-xL. Cancer Res 55: 2262–2265
Taga T, Hibi M, Hirata Y, Yamasaki K, Yasukawa K, Matsuda T, Hirano T,
Kishimoto T (1989) Interleukin-6 triggers the association of its receptor
with a possible signal transducer, gp130. Cell 58: 573–581
Usuda J, Okunaka T, Furukawa K, Tsuchida T, Kuroiwa Y, Ohe Y, Saijo N,
Nishio K, Konaka C, Kato H (2001) Increased cytotoxic effects of
photodynamic therapy in IL-6 gene transfected cells via enhanced
apoptosis. Int J Cancer 93: 475–480
Wei LH, Kuo ML, Chen CA, Chou CH, Lai KB, Lee CN, Hsieh CY (2003)
Interleukin-6 promotes cervical tumor growth by VEGF-dependent
angiogenesis via a STAT3 pathway. Oncogene 22: 1517–1527
Wong TW, Tracy E, Oseroff AR, Baumann H (2003) Photodynamic therapy
mediates immediate loss of cellular responsiveness to cytokines and
growth factors. Cancer Res 63: 3812–3818
Yom SS, Busch TM, Friedberg JS, Wileyto EP, Smith D, Glatstein E, Hahn SM
(2003) Elevated serum cytokine levels in mesothelioma patients who have
undergone pleurectomy or extrapleural pneumonectomy and adjuvant
intraoperative photodynamic therapy. Photochem Photobiol 78: 75–81
Zhuang S, Ouedraogo GD, Kochevar IE (2003) Downregulation of
epidermal growth factor receptor signaling by singlet oxygen through acti-
vation of caspase-3 and protein phosphatases. Oncogene 22: 4413–4424
IL-6 trans signalling and photodynamic therapy
L-H Wei et al
1522
British Journal of Cancer (2007) 97(11), 1513–1522 & 2007 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
s